Achieve Life Sciences Inc ACHV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $5.60
- Day Range
- $5.47–5.79
- 52-Week Range
- $2.00–6.15
- Bid/Ask
- $5.60 / $5.74
- Shares Outstanding
- 102.66M
- Market Cap
- $590.29M
- Volume/Avg
- 1M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 28
Valuation
|
Metric
|
ACHV
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 27.95 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
ACHV
Financial Strength
|
Metric
|
ACHV
|
|---|---|
Quick Ratio | 2.47 |
Current Ratio | 2.62 |
Interest Coverage | −57.88 |
Quick Ratio
ACHV
Profitability
|
Metric
|
ACHV
|
|---|---|
Return on Assets (Normalized) | −108.13% |
Return on Equity (Normalized) | −195.80% |
Return on Invested Capital (Normalized) | −131.45% |
Return on Assets
ACHV
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Vsndsqfr | Qqyfvv | $111B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Bfdwrhnxg | Vnymhxw | $63B | |||
| argenx SE ADR
ARGX
| Nffprcchq | Nvctl | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Kxvhgmp | Hkkwv | $39B | |||
| Royalty Pharma PLC Class A
RPRX
| Bmhrznfzv | Fjhdwq | $25B | |||
| BioNTech SE ADR
BNTX
| Fnzjgzxzv | Lht | $22B | |||
| Incyte Corp
INCY
| Jjcwlcq | Hfmz | $21B | |||
| Moderna Inc
MRNA
| Lnjfyfwfq | Rskv | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Rcvgmqw | Ytbf | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Llzsnztz | Hfdf | $13B |
United States